Arévalo LA, Sánchez RL

Language: Spanish
References: 25
Page: 240-246
PDF size: 205.26 Kb.

ABSTRACT

Background: Psoriasis is a common problem in dermatology. Widespread cutaneous involvement with or without joint involvement, are indications of systemic therapy. Nowadays it should include the biological agents, known by its target and a satisfactory efficacy-safety ratio.Their value is based on randomized clinical trials.
Materials and methods: To characterize the therapeutic profile of these drugs with emphasis in the wellfare of our patients, from our referral hospital, we obtained detail clinical information.
Results: The study included 41 patients under treatment either with infliximab, adalimumab and etanercept, most of them men ( 31 with mean age, 54 years), plaque psoriasis (87.9%) and the mean severity markers were, PASI 11.2 and body surface affected 22%. Almost all the cases had been previously treated with methotrexate and cyclosporine. Efficacy defined as a clinical improvement at least 75% was reached in 70%. Adverse effects were seen in 34%, usually as non-relevant upper airways and skin infections.
Conclusion: Biological agents are an effective and safe alternative in psoriasis patients with previous failure to other systemic drugs.

REFERENCES

1. Gudjonsson J, Elder J. “Psoriasis”. En: Wolff K, Goldsmith LA, et al. Fitzpatrick’s Dermatology in General Medicine. 7ª ed., New York, EEUU: Mc Graw Hill Medical; 2008: 169-193.

2. Patel RV, Lebwohl M. “Psoriasis”. Ann Intern Med 2011; 155: ITC 2-16.

3. Husted JA, Thavaneswaran A, Chandran V, Eder L, Rosen ChF, Cook RJ, et al. “Cardiovascular and other comorbidities in patients with psoriatic arthritis: A comparison with patients with psoriasis”. Arthritis Care Res 2011; 63: 1729-1735.

4. Gottlieb AB, Chao Ch, Dann F. “Psoriasis comorbidities”. J Dermatol Treatment 2008; 19: 5-21.

5. Cohen AD, Sherf M, Vidavsky L, Vardy DA, Shapiro J, Meyerovitch J. “Association between psoriasis and metabolic syndrome. A cross sectional study”. Dermatology 2008; 216: 152-155.

6. Menter A, Korman NJ, Elmets CA, Feldman SR, Gelfand JM, Gordon KB, et al. “Guidelines of care for the management of psoriasis and psoriatic arthritis”. J Am Acad Dermatol 2009; 61: 451-485.

7. Smith CH, Anstey AV, Barker JNWN, Burden AD, Chalmers RJG, Chandler DA, et al. “British Association of Dermatologists’ guidelines for biological interventions for psoriasis 2009”. Br J Dermatol 2009; 161: 987-1019.

8. Scanlon JV, Exter BP, Steinberg M, Jarvis CI: Ustekinumab. “Treatment of adult moderate-to-severe chronic plaque psoriasis”. Ann Pharmacother 2009; 43: 1456-1465.

9. Pathirana D, Ormerod AD, Saiag P, Smith C, Spuls PI, Nast A, et al. “European S3-Guidelines on the systemic treatment of psoriasis vulgaris”. JEADV 2009; 23 (Suppl 2): 5-70.

10. Hsu S, Papp KA, Lebwohl MG, Bagel J, Blauvelt A, Callis Duffin K, et al. “Consensus guidelines for the management of plaque psoriasis”. Arch Dermatol 2012; 148: 95-102.

11. Castelo-Soccio L, Van Voorhees AS. “Long-term efficacy of biologics in dermatology”. Dermatol Ther 2009; 22: 22-33.

12. Reich K, Burden AD, Eaton JN, Hawkins NS. “Efficacy of biologics in the treatment of moderate to severe psoriasis: a network meta-analysis of randomized controlled trials”. Br J Dermatol 2012; 166: 179-188.

13. Lima XT, Seidler EM, Lima HC, Kimball AB. “Long-term safety of biologics in dermatology”. Dermatol Ther 2009; 22: 2-21.

14. Van Lümig PPM, Driessen RJB, Berends MAM, Boezeman JBM, Van de Kerkhof PCM, De Jong EMGJ. “Safety of treatment with biologics for psoriasis in daily practice: 5-year data”. JEADV 2012; 26: 283-291.

15. Doherty SD, Van Voorhees A, Lebwohl MG, Korman NJ, Young MS, Hsu S. “National Psoriasis Foundation consensus statement on screening for latent tuberculosis infection in patients with psoriasis treated with systemic and biologic agents”. J Am Acad Dermatol 2008; 59:209-217.

16. Driessen RJB, Boezeman JB, Van de Kerkhof PCM, De Jong EMGL. “Three-year registry data on biological treatment for psoriasis: the influence of patients characteristics on treatment outcome”. Br J Dermatol 2009; 160: 670-675.

17. Langley RG, Ellis Ch N. “Evaluating psoriasis with Psoriasis Area and Severity Index, Psoriasis Global Assessment, and Lattice System Physicians’s Global Assessment”. J Am Acad Dermatol 2004; 51: 563-9.

18. Nebeker JR, Barach P, Samore MH. “Clarifying adverse drug events: A clinician’s guide to terminology, documentation, and reporting”. Ann Intern Med 2004; 140: 795-801.

19. Warren RB, Brown BC, Lavery D, Aschcroft DM, Griffiths CEM. “Biological therapies for psoriasis: practical experience in a U.K. tertiary referral centre”. Br J Dermatol 2009; 160: 162-169.

20. Talamonti M, Trili M, Botti E, Spallone G, Chimentis S, Constanzo A. “Patients with moderate to severe plaque psoriasis: one year after the European Medicines Agency recommendation of efalizumab suspension”. Dermatology 2011; 222: 250-255.

21. Channual J, Wu JJ, Dann FJ. “Effects of tumor necrosis factor-α blockade on metabolic syndrome components in psoriasis, and psoriatic arthritis and additional lessons learned from rheumatoid arthritis”. Dermatol Ther 2009; 22: 61-73.

22. Griffiths CEM, Strober BE, Van de Kerkhof P, Ho V, Fidelus-Gort R, Yeilding N, et al. “Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis”. N Engl J Med 2010; 362: 118-128.

23. Dalaker M, Bonesrønning JH. “Long-term maintenance treatment of moderate-to-severe plaque psoriasis with infliximab in combination with methotrexate or azathioprine in a retrospective cohort”. JAEDV 2009; 23: 277-282.

24. Domms S, Cinatl J, Mrowietz U. “The impact of treatment with tumor necrosis factor-α antagonists on the course of chronic viral infections: a review of the literature”. Br J Dermatol 2008; 159: 1217-1228.

25. Van Lümig PPM, Driessen RJB, Roebfs-Thijssen MAMA, Boezeman JBM, Van de Kerkhof PCM, De Jong EMGJ. “Relevance of laboratory investigations in monitoring patients with psoriasis on etanercept or adalimumab”. Br J Dermatol 2011; 165: 375-382.